---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117219"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:42:33.456300+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vaccitech Q3 net income $8.2M; cash $200.1M; first patient dosed in VTP-300 Phase 2b

## Summary
- Net income of $8.2M ($0.22 per share) vs $15.7M in Q2 2022; revenue fell to $6.2M from $17.1M as no milestones.
- Cash and equivalents $200.1M as of Sep 30, 2022, down from $214.1M at Dec 31, 2021; cash runway into Q1 2025.
- Dosed first patient in Phase 2b trial of VTP-300 for HBV; Phase 1b/2a data showed HBsAg reduction in CHB patients.
- Promoted Gemma Brown to CFO effective Sep 20, 2022.
- Expects to open Phase 1/2 trial for prostate cancer candidate VTP-850 in Q4 2022; IND submissions for SNAPvax programs in 2023.

## SEC filing metadata
- accession: 0001104659-22-117219
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465922117219/0001104659-22-117219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465922117219/tm2230034d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117219
- JSON: https://secwatch.observer/filing/0001104659-22-117219.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117219.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported third quarter ended September 30, 2022 results: revenue $6.2 million, net income $8.2 million, EPS $0.22 both per fully diluted share and per basic share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $6.2 million
  - Net income: $8.2 million
  - EPS: $0.22 both per fully diluted share and per basic share
  - Result: reported results
  source text: Revenues comprised primarily of the Company’s share of milestone and royalty payments received by OUI from AstraZeneca related to commercial sales of Vaxzevria ® . Revenues were $6.2 million in the third quarter of 2022 compared to $17.1 million in the second quarter of 2022, with the reduction attributable to no milestones being achieved in the third quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000110465922117219/0001104659-22-117219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.